Showing results (1-10 of 968) with videos related to
Sort By:
Pageof 97
Blood Cancer Journal|May 28, 2021
FLT3 mutated acute myeloid leukemia: 2021 treatment algorithmNaval Daver, Sangeetha Venugopal, Farhad RavandiCurrent Hematologic Malignancy Reports|February 25, 2021
An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid LeukemiaSangeetha Venugopal, Naval Daver, Farhad RavandiExpert Review of Hematology|February 25, 2016
Acute myeloid leukemia: advancing clinical trials and promising therapeuticsNaval Daver, Jorge Cortes, Hagop Kantarjian, et al.Current Opinion in Hematology|December 6, 2017
Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitorsRita Assi, Hagop Kantarjian, Farhad Ravandi, et al.Therapeutic Advances in Hematology|February 26, 2019
Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemiaNicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.Leukemia & Lymphoma|September 25, 2019
CPX-351 (vyxeos) in AMLMansour Alfayez, Hagop Kantarjian, Tapan Kadia, et al.Cancer Management and Research|October 22, 2019
Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient SelectionHussein A Abbas, Mansour Alfayez, Tapan Kadia, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2012
The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemiaHun Ju Lee, Naval Daver, Hagop M Kantarjian, et al.Blood Cancer Journal|June 10, 2022
Resistance to targeted therapies: delving into FLT3 and IDHSai Prasad Desikan, Naval Daver, Courtney DiNardo, et al.Current Oncology Reports|August 1, 2025
Current Treatment Strategies for FLT3-Mutated Acute Myeloid Leukemia in Patients not Candidates for Intensive ChemotherapyAlex Bataller, Nicholas J Short, Naval Daver, et al.Pageof 97